Calibrated automated thrombin generation in frozen-thawed platelet-rich plasma to detect hypercoagulability.
To enhance the practical applicability of the calibrated automated thrombogram (CAT) we investigated whether frozen-thawed platelet-rich plasma (ft-PRP) can be used to assess the function of the protein C inhibitory pathway, while preserving the natural phospholipid composition. Recalcified ft-PRP triggered with 0.5 pM recombinant human tissue factor shows a median thrombin potential of 1,779 nM x min, against 1,576 nM x min for fresh PRP. To obtain approximately 70% inhibition, 6.7 nM activated protein C (APC) has to be added, instead of 25 nM in fresh PRP; so the relative APC resistance of PRP appears to depend upon the presence of intact platelets. Factor VIII, added to normal ft-PRP to obtain a concentration of 3.3 U/ml, increases the thrombin potential in the presence of APC 1.5-fold, from 524 to 808 nM x min, in keeping with previously published increases in thrombotic risk in patients with high factor VIII levels. We conclude that thrombography in ft-PRP, with and without added APC, can be used to assess known risk factors for thrombosis, which allows the design of large clinical studies aimed at proving the relationship between thrombin potential and clinical outcome.
Regnault
Véronique
V
INSERM ERIT-M 0323 et EA 3452, Faculté de Médecine, Université Henri Poincaré, CHU de Nancy, Nancy, France. regnault@hemato.u-nancy.fr
Béguin
Suzette
S
Lecompte
Thomas
T
D001331:Automation; D001780:Blood Coagulation Tests / Q000295:instrumentation / Q000379:methods*; D001793:Blood Preservation / Q000379:methods; D002138:Calibration; D003374:Coumarins / Q000032:analysis; D015925:Cryopreservation; D004789:Enzyme Activation; D005169:Factor VIII / Q000494:pharmacology; D005456:Fluorescent Dyes / Q000032:analysis; D005470:Fluorometry / Q000295:instrumentation / Q000379:methods*; D006801:Humans; D009842:Oligopeptides / Q000032:analysis; D010949:Plasma; D010976:Platelet Count; D011486:Protein C / Q000378:metabolism; D012307:Risk Factors; D012680:Sensitivity and Specificity; D013917:Thrombin / Q000032:analysis / Q000096:biosynthesis*; D019851:Thrombophilia / Q000097:blood* / Q000175:diagnosis
D003374:Coumarins; D005456:Fluorescent Dyes; D009842:Oligopeptides; D011486:Protein C; C411346:benzyloxycarbonyl-glycyl--glycyl-arginine-4-methylcoumaryl-7-amide; D005169:Factor VIII; D013917:Thrombin